Updated:
Zhongke Pengkai Capital
Zhongke Pengkai Capital is an early-stage private equity firm based in Shanghai, with investment activity focused on seed and venture-stage rounds.
Zhongke Pengkai Capital
Zhongke Pengkai Capital is an early-stage private equity firm based in Shanghai, with investment activity focused on seed and venture-stage rounds. The firm's name embeds 'Zhongke,' a common abbreviation for the Chinese Academy of Sciences (CAS), indicating likely institutional proximity to CAS-affiliated research institutes or technology transfer entities. This origin gives the firm unusual access to a pipeline of scientist-founded startups in fields such as semiconductors, advanced materials, and precision instrumentation. The firm invests primarily through direct equity in seed and Series A rounds, occasionally participating in later venture stages. Its portfolio concentrates on hard-technology verticals where technical moats are high and commercialization cycles are long — areas underserved by traditional consumer-tech venture capital. Geographic coverage is centered on Shanghai and the Yangtze River Delta innovation corridor, though the firm reviews deals across major Chinese tech hubs including Beijing and Shenzhen. No specific portfolio company names were publicly confirmed at time of research. Team size and AUM figures are not publicly disclosed. The firm's operational structure likely mirrors the standard local RMB fund model common among research-institution-affiliated investors, with capital raised from government guidance funds, state-owned enterprises, and institutional limited partners. No adjacent philanthropic or operating vehicles have been identified. No significant leadership changes or fund closes have been reported in the past 24 months. What distinguishes the firm from independent Chinese venture managers is its embeddedness in the CAS translational-research machinery. This architecture provides early visibility into government-funded labs' commercialization pipelines, creating a deal-sourcing advantage that purely financial sponsors cannot easily replicate. The trade-off is a mandate alignment with Chinese industrial policy objectives that may constrain sector selectivity.
General information
Firm type
Private Equity
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Shanghai, China
Frequently asked questions
What is the firm's relationship to the Chinese Academy of Sciences?
The name prefix 'Zhongke' strongly indicates institutional affiliation with the Chinese Academy of Sciences or a CAS-linked technology transfer platform, though the exact legal relationship is not publicly detailed. In China, 'Zhongke'-branded investment entities typically act as commercialization arms for CAS-affiliated research, translating laboratory innovations into for-profit ventures. This structure provides proprietary access to scientific pipelines that independent venture firms cannot replicate.
Does Zhongke Pengkai Capital invest outside of mainland China?
No publicly verifiable cross-border investments have been identified. The firm's mandate appears concentrated on domestic Chinese startups, with a geographic focus on the Shanghai and Yangtze River Delta region. Investments outside China would likely require a separate USD-denominated vehicle, which has not been disclosed.
What investment stages does the firm target?
The firm targets early-stage rounds, including seed and general venture. This suggests entry points at pre-revenue or early-revenue phases for deep-tech and advanced manufacturing companies. No later-stage growth or buyout activity has been documented.
Is the firm open to co-investing with foreign GPs?
No public record confirms co-investment activity with foreign general partners. Given the firm's likely RMB-denominated fund structure and CAS institutional moorings, cross-border co-investments would face both currency-control and technology-transfer regulatory scrutiny. Most comparable CAS-affiliated funds deploy alongside domestic Chinese LPs.
Which sectors does the firm explicitly avoid?
The firm's mandate appears focused on hard-technology verticals rooted in physical science and engineering, implying a de facto avoidance of consumer internet, platform marketplaces, and business-model-innovation plays that dominate generalist Chinese VC portfolios. No explicit negative sector screening has been published.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: